Having recently gone through the faecal test and a colonoscopy the convenience of a blood test stands out like bull's. I think everyone realises that having to sample your crap over two dumps - how many cheat and take both samples from the same batch? - store it in the fridge and then post it before the PO closes for the day - even at my local GPO last mail for the day is 4:00pm - is just a pain in the backside (so to speak).
But even with the streamlined preparation they use for colonoscopies these days - 2 days of restricted diet, half a day on the can, three hours with knockout drops then 24 hours without driving - it is still a major inconvenience. In contrast, for those who have annual blood tests there is nothing extra to do with ColoSTAT.
The other thing that stood out is what a big business colonoscopies are. I went to a centre dedicated to colonoscopies and endoscopies. Three receptionists, maybe four registered nurses, 15 beds, a couple of procedure rooms, with specialists coming and going. 800,000 colonoscopies a year in Australia at say $900 gross a pop = $720m just for the procedure (let alone additional contact with the specialists). To say that ColoSTAT could be disruptive to this niche sector is an understatement.
It seems to me that what this company is offering is so blindingly obviously a winner I will be totally gutted if it is not the standard for colon cancer testing within a few years. I've had a couple of these "sure-thing" investments go bad - bad luck or just poor investment practice - so I know how sickening the feeling will be. But someone has to win the lottery and the odds on this company are far less than those for a lottery.
RHY Price at posting:
$1.18 Sentiment: Hold Disclosure: Held
